Show simple item record

AuthorAl-Nesf, Maryam A. Y.
AuthorAbdesselem, Houari B.
AuthorBensmail, Ilham
AuthorIbrahim, Shahd
AuthorSaeed, Walaa A. H.
AuthorMohammed, Sara S. I.
AuthorRazok, Almurtada
AuthorAlhussain, Hashim
AuthorAly, Reham M. A.
AuthorAl Maslamani, Muna
AuthorOuararhni, Khalid
AuthorKhatib, Mohamad Y.
AuthorHssain, Ali Ait
AuthorOmrani, Ali S.
AuthorAl-Kaabi, Saad
AuthorAl Khal, Abdullatif
AuthorAl-Thani, Asmaa A.
AuthorSamsam, Waseem
AuthorFarooq, Abdulaziz
AuthorAl-Suwaidi, Jassim
AuthorAl-Maadheed, Mohammed
AuthorAl-Siddiqi, Heba H.
AuthorButler, Alexandra E.
AuthorDecock, Julie V.
AuthorMohamed-Ali, Vidya
AuthorAl-Ejeh, Fares
Available date2023-08-28T09:09:49Z
Publication Date2022
Publication NameNature Communications
ResourceScopus
ISSN20411723
URIhttp://dx.doi.org/10.1038/s41467-022-28639-4
URIhttp://hdl.handle.net/10576/46831
AbstractCOVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. 2022, The Author(s).
SponsorThe authors would like to thank all the patients, volunteers, and the healthcare co-workers from Allergy and Immunology Section-HMC, and Dr. Mohamed G.H. Mohamedali, Mr. Hassen Maatoug, and Mr. Ahmed Soliman from Hezm Mebairek General Hospital-HMC for developing disposable racks for samples transportation, tubes labeling, blood collection, and handling. We thank the support provided by Qatar University Biomedical Research Centre, Biosafety Level 3, and Associate Professor Hadi M. Yassine (M.Sc., Ph.D.). We also acknowledge the help of the Anti-Doping Lab-Qatar (ADLQ) and Qatar Red Crescent (QRC) for recruiting control samples. This work was supported by a grant fund from Hamad Medical Corporation (fund number MRC-05-003) and core funding from Qatar Biomedical Research Institute (QBRI).
Languageen
PublisherNature Research
SubjectInfection
SARS-CoV-2
Translational immunology
Viral infection
TitlePrognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
TypeArticle
Issue Number1
Volume Number13
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record